SQI Diagnostics Inc., a life sciences company, develops and commercializes proprietary technologies and products for advanced multiplexing diagnostics in Canada. The company offers sqidworks diagnostic platform, a fully-automated microarray processing and analytical system; sqidlite benchtop diagnostic platform, a fully automated bench top microarray processing and analytical system; and sqid-X, a semi-automated bench-top platform. Its products are used in immunogenicity and bioanalysis, IVD and clinical, biomarkers, and assay development applications. SQI Diagnostics Inc. has a co-develop and licensing agreement with McMaster University Department of Engineering to develop chip technology for use in multi-array disease testing; and research and development agreements with University Health Network to create and license rapid multiplexed protein assays, as well as a point-of-care diagnostic device to enable transplant surgeons assess the suitability of lungs and other organs for transplantation. The company was founded in 1999 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Medical/Nursing Services
Sub-IndustryN/A
SectorHealth Services
CIKN/A
Phone(416) 674-9500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees42
Next Earnings DateN/A
OptionableNot Optionable
SQI Diagnostics (OTCMKTS:SQIDF) Frequently Asked Questions
What is SQI Diagnostics' stock symbol?
SQI Diagnostics trades on the OTCMKTS under the ticker symbol "SQIDF."
How were SQI Diagnostics' earnings last quarter?
SQI Diagnostics Inc. (OTCMKTS:SQIDF) issued its quarterly earnings data on Tuesday, January, 28th. The company reported ($0.03) earnings per share (EPS) for the quarter. View SQI Diagnostics' Earnings History.
Has SQI Diagnostics been receiving favorable news coverage?
News coverage about SQIDF stock has trended extremely negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. SQI Diagnostics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for SQI Diagnostics.
What other stocks do shareholders of SQI Diagnostics own?
Who are SQI Diagnostics' key executives?
SQI Diagnostics' management team includes the folowing people:
- Mr. Andrew Morris, CEO, Pres & Director (Age 53)
- Ms. Patricia Lie CPA, CA, VP of Fin. & Admin.
- Dr. Eric Brouwer, Chief Scientific Officer
- Dr. Peter Lea Ph.D., Founder (Age 74)
- Mr. Russell Peloquin, VP of Global Commercial Operations
How do I buy shares of SQI Diagnostics?
Shares of SQIDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is SQI Diagnostics' stock price today?
One share of SQIDF stock can currently be purchased for approximately $0.06.
What is SQI Diagnostics' official website?
How can I contact SQI Diagnostics?
The company can be reached via phone at (416) 674-9500.
MarketBeat Community Rating for SQI Diagnostics (OTCMKTS SQIDF)
MarketBeat's community ratings are surveys of what our community members think about SQI Diagnostics and other stocks. Vote "Outperform" if you believe SQIDF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SQIDF will underperform the S&P 500 over the long term. You may vote once every thirty days.
